Choreo LLC Purchases New Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Choreo LLC acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,026 shares of the biotechnology company’s stock, valued at approximately $106,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the period. Two Sigma Advisers LP increased its stake in shares of BioCryst Pharmaceuticals by 13.6% during the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after purchasing an additional 261,500 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the last quarter. Finally, FMR LLC lifted its position in shares of BioCryst Pharmaceuticals by 2.4% during the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock worth $15,112,000 after acquiring an additional 46,110 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ:BCRX opened at $9.05 on Friday. The company has a market cap of $1.87 billion, a PE ratio of -14.84 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.11. The stock has a 50 day moving average of $7.86 and a 200 day moving average of $7.77.

Wall Street Analyst Weigh In

BCRX has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC increased their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Evercore ISI lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.